Francesco Iorio

Francesco Iorio

Franceso Iorio è un bioinformatico, attualmente group leader del centro di ricerca per la biologia computazionale di HT e team leader del Wellcome Sanger Institute di Hixton (Regno Unito).  Francesco lavora principalmente su metodi bioinformatici per la farmaco-genomica, la scoperta di target terapeutici, il riposizionamento di farmaci e l’analisi di big-data in ambito biomedico. Il suo lavoro si concentra sul cancro, sulle malattie rare e i disturbi neurodegenerativi, quali per esempio Alzheimer e Parkinson. Francesco sta formando il suo gruppo per l’avvio della sua attività di ricerca,  dividendosi tra Milano e Cambridge

Pubblicazioni

  • 10/2020 - Nucleic Acid Research

    Project Score database: a resource for investigating cancer cell dependencies and prioritizing therapeutic targets

    CRISPR genetic screens in cancer cell models are a powerful tool to elucidate oncogenic mechanisms and to identify promising therapeutic targets. The Project Score database (https://score.depmap.sanger.ac.uk/) uses genome-wide CRISPR–Cas9 dropout screening data in hundreds of highly annotated cancer cell models to identify genes required for cell fitness and prioritize novel oncology targets. The Project Score […]

  • 08/2020 - Patterns

    Identification of Intrinsic Drug Resistance and Its Biomarkers in High-Throughput Pharmacogenomic and CRISPR Screens

    High-throughput drug screens in cancer cell lines test compounds at low concentrations, thereby enabling the identification of drug-sensitivity biomarkers, while resistance biomarkers remain underexplored. Dissecting meaningful drug responses at high concentrations is challenging due to cytotoxicity, i.e., off-target effects, thus limiting resistance biomarker discovery to frequently mutated cancer genes. To address this, we interrogate subpopulations […]

  • 08/2020 - Pigment Cell and Melanoma Research

    Analysis of CRISPR‐Cas9 screens identify genetic dependencies in melanoma

    Targeting the MAPK signaling pathway has transformed the treatment of metastatic melanoma. CRISPR‐Cas9 genetic screens provide a genome‐wide approach to uncover novel genetic dependencies that might serve as therapeutic targets. Here, we analyzed recently reported CRISPR‐Cas9 screens comparing data from 28 melanoma cell lines and 313 cell lines of other tumor types in order to […]

  • 07/2020 - Molecular Systems Biology

    Drug mechanism‐of‐action discovery through the integration of pharmacological and CRISPR screens

    Low success rates during drug development are due, in part, to the difficulty of defining drug mechanism‐of‐action and molecular markers of therapeutic activity. Here, we integrated 199,219 drug sensitivity measurements for 397 unique anti‐cancer drugs with genome‐wide CRISPR loss‐of‐function screens in 484 cell lines to systematically investigate cellular drug mechanism‐of‐action. We observed an enrichment for […]

  • 05/2020 - Cell Systems

    CELLector: Genomics-Guided Selection of Cancer In Vitro Models

    Selecting appropriate cancer models is a key prerequisite for maximizing translational potential and clinical relevance of in vitro oncology studies. We developed CELLector: an R package and R Shiny application allowing researchers to select the most relevant cancer cell lines in a patient-genomic-guided fashion. CELLector leverages tumor genomics to identify recurrent subtypes with associated genomic signatures. It then evaluates […]